|
Video: What is a Stock Split?
|
|
Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. According to our Karyopharm Therapeutics stock split history records, Karyopharm Therapeutics has had 0 splits. | |
|
Karyopharm Therapeutics (KPTI) has 0 splits in our Karyopharm Therapeutics stock split history database.
Looking at the Karyopharm Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Karyopharm Therapeutics shares, starting with a $10,000 purchase of KPTI, presented on a split-history-adjusted basis factoring in the complete Karyopharm Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$31.92 |
|
End price/share: |
$1.51 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.27% |
|
Average Annual Total Return: |
-26.30% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$473.19 |
|
Years: |
10.00 |
|
|
|
|
|